Why insider trading matters?
What separates FormWhispers.com from others is that we created it to meet our own needs and we use it everyday to make better investment decisions. We will keep improving it to serve us better and to serve you better.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is developing UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate, which is in Phase I clinical trials for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL; ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma.
| Trade Date | Insider | Title | Buy/Sell | #Shares | Price | Value | Option |
|---|---|---|---|---|---|---|---|
| 2021-08-16 | Bhavnagri Veer | General Counsel | Sell | 5,000 | $21.00 | $104,994 | Yes |
| 2021-06-15 | Bhavnagri Veer | General Counsel | Sell | 5,000 | $25.32 | $126,600 | Yes |
| 2021-05-18 | Bhavnagri Veer | General Counsel | Sell | 5,000 | $30.00 | $150,000 | Yes |
| 2021-04-15 | Bhavnagri Veer | General Counsel | Sell | 10,000 | $32.05 | $320,517 | Yes |
| 2021-03-15 | Bhavnagri Veer | General Counsel | Sell | 16,623 | $37.95 | $630,798 | Yes |
| 2020-10-06 | Bhavnagri Veer | General Counsel | Sell | 10,000 | $40.00 | $400,000 | Yes |
| 2020-10-01 | Bhavnagri Veer | General Counsel | Sell | 25,000 | $36.52 | $912,913 | Yes |
| 2020-09-01 | Bhavnagri Veer | General Counsel | Sell | 25,000 | $35.36 | $883,966 | Yes |
| 2020-08-03 | Bhavnagri Veer | General Counsel | Sell | 31,553 | $36.89 | $1,164,121 | Yes |
Insider Smart
Insider Smart